FCGR2C and neoplasm: Since the classic FCGR2C-ORF haplotype leads to expression of the activating FcγRIIc on NK cells, neutrophils, monocytes (Figure 2) and macrophages (17), it may contribute to killing of tumor cells by antibody-dependent cellular cytotoxicity by these cells, and could potentially be a stronger predictor of treatment success.